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Abstract
Iron oxide nanoparticles have received sustained interest
for biomedical applications as synthetic approaches are
continually developed for control of nanoparticle proper‐
ties. However, many approaches focus solely on the
material, rather than the complete optimization of synthe‐
sis and functionalization together to enhance translation
into biological systems. Presented herein is a modified seed
growth method designed for obtaining optimal nanoparti‐
cle properties and ease of surface functionalization for long
term stability. With a one or two addition process, iron
oxide nanoparticles were produced in crystallite sizes
ranging from 5-15 nm using only benzyl alcohol and an iron
precursor. In the functionalization process, concentration
variations were required for stabilizing different nanopar‐
ticle sizes. Radio frequency induction heating experiments
of various crystallite and hydrodynamic sizes verified that
the heating efficiency greatly increased while approaching
the 15 nm crystallite, and suggested an important role of
the overall particle size on heating efficiency. Initial in
vitro experiments with the functionalized nanoparticles
showed success in providing hyperthermia-induced
tumour cell killing without an increase in the temperature
of the cell suspension medium. This demonstrates the
potential for nanoparticle-based hyperthermia to provide
a therapeutic effect while limiting normal tissue damage.
Keywords biocompatible materials, cancer therapy,
hyperthermia, benzyl alcohol, magnetic iron oxide nano‐
particles
1. Introduction
In 1957 Gilchrist first reported the idea of using magnetic
particles for hyperthermia treatment of tumours.[1]
Hyperthermia is often divided into three temperature
ranges that have various effects and interactions with other
therapies.[2,3] Mild hyperthermia (39-42°C) is considered
non-lethal temperature elevation and has been shown to
sensitize tumours to chemotherapy or radiation by in‐
creased drug perfusion and oxygenation.[3-5] Moderate
hyperthermia (41-46°C) causes cells to experience heat
stress, promotes protein degradation and interrupts vital
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cellular processes eventually leading to apoptosis.[6-8]
Thermoablation (>45°C) generates enough heat to directly
destroy local tumour cells and tissues.[6,8,9] In order to
produce these heating effects in tumours by magnetic
particles, an external radiofrequency (RF) alternating
current (AC) magnetic field is applied which heats mag‐
netic particles by eddy currents, dielectric losses, or
hysteretic heating.[1] The extent and rate of particle heating
depends on the size, conductivity and magnetic properties
of the material.[1,2,10-13] Gilchrist found that the frequen‐
cy and field strength applied must be optimized to provide
minimal heating of healthy tissue due to dielectric loss and
maximize hysteretic heating of the magnetic particles.[1]
Research into magnetic particle-based hyperthermia has
shifted  from  larger  multi-domain  particles,  similar  to
Gilchrist’s  research,  to  smaller  single-domain  and
superparamagnetic materials. The primary reason for this
shift  is  that  superparamagnetic  nanoparticles  are  much
more efficient at absorbing power to generate heat than
microparticles.[2]  Superparamagnetic  nanoparticles
generate  heat  by two mechanisms.  The Néel  relaxation
mechanism generates  heat  through quickly altering the
direction of magnetic moments with respect to the crystal
lattice.[6] The Brownian mechanism generates heat as a
result  of  the viscosity of  the media resisting the physi‐
cal  rotation  of  the  nanoparticles  in  an  applied  AC
magnetic  field.[14]  The  internal,  Néel,  and  external,
Brownian,  sources  of  friction  generate  heat  by  loss  of
thermal  energy.[14]  Several  factors  can  affect  which
mechanism of heating dominates, such as size, polydis‐
persity, crystal structure, shape, and magnetic anisotropy.
[14]  However,  it  has been determined that  the average
crystallite size and narrow size distribution are two of the
most  important  factors  in  maximizing  energy  absorp‐
tion  and  heat  production.[13,15]  Other  reasons  for
shifting to nanoparticles are that larger particles tend to
be  more  invasive,  have  a  higher  potential  for  adverse
damage to surrounding healthy cells, and do not generate
uniform heating.[2] Furthermore, unlike larger magnetic
particles, superparamagnetic nanoparticles do not retain
their  magnetism after  removal  of  an  external  magnetic
field  and  are  thus  less  likely  to  aggregate,  which  pro‐
longs blood circulation time.[16]  Furthermore,  with the
combination  of  modern  medicine  and  nanotechnology,
nanoparticles can be specifically targeted to cancer cells
to  provide  minimal  invasiveness,  and  more  local  and
confined heating.[2,6,17,18]
More specifically, iron oxide nanoparticles are a primary
candidate for nanomedicine therapeutic applications in
part due to their RF induction heating properties, as well
as being biocompatible and biodegradable.[15,16] In
addition, they can be classified as a theranostic agent[19-22]
providing diagnostic imaging capabilities in the form of a
magnetic resonance imaging (MRI) contrast[23,24] and
therapeutic potential by means of magnetic fluid hyper‐
thermia (MFH).[15,24,25] Superparamagnetic iron oxide
nanoparticles functionalized with aminosilanes are
currently undergoing clinical trials in Germany for MFH
treatment of glioblastoma and prostate cancer.[17,25,26]
The optimal iron oxide nanoparticles for heat generation by
RF induction heating have been shown to have a crystallite
size of 15-16 nanometres (nm).[27,28] This size gives the
ideal combination of heating mechanisms with Néel
relaxation being the dominant process.[29] Above this size,
Brownian relaxation becomes the dominant heating
mechanism, which yields lower heat generation.[29] Thus,
optimization and investigation of iron oxide nanoparticle
synthesis to control and obtain the best combination of
crystallite size, particle size, monodispersity and magnetic
properties is of continually growing interest.
There are currently several synthetic strategies to prepare
superparamagnetic iron oxide nanoparticles using thermal
decomposition methods.[30-33] The use of non-polar
solvents allows for tunable size, high crystallinity, easy
scale-up, and a narrow size distribution of nanoparticles,
but they can be more difficult to phase transfer, function‐
alize and purify for biological applications. In addition,
most of these approaches rely on several seed growth steps
with intermediate wash steps, multiple solvents and
capping agents to obtain the desired 15 nm crystallite size.
[31,34] The synthesized nanoparticles then undergo
rigorous phase transfer processes and surface functionali‐
zation methods to produce a biologically stable colloidal
suspension. Magnetic fluid hyperthermia and nanomedi‐
cine in general rely heavily on maintaining the biological
stability of the nanoparticles and the ability to carry
targeting ligands to increase the affinity to tumour cells.
[17,18,35] Thus, synthesizing nanoparticles that are easily
functionalized, purified, stable in various media and can be
further functionalized with targeting or therapeutic
modalities is of paramount importance.
In this paper, we present a modified seed growth approach
to produce nanoparticles with crystallite sizes of 5-15 nm
and optimization of functionalization parameters for
biological applications. The main purpose of the investiga‐
tion is to optimize previous benzyl alcohol metal oxide
synthesis[36-39] for a one-pot addition setup, with fewer
washing steps, that produces iron oxide nanoparticles that
are easier and more efficiently surface functionalized than
previously reported methods.[31,34] Benzyl alcohol was
used as the solvent, capping agent and reducing agent for
the combined reduction and thermal decomposition of iron
(III) acetylacetonate (Fe(acac)3). Benzyl alcohol is found
naturally in oils of plants and used in cosmetic products,
[40] as a flavour and fragrance additive,[40-42] and as a
preservative of injectable drugs,[43] and has an overall low
toxicity. Several synthetic parameters such as temperature,
concentration, time and addition of extra iron precursors
were investigated to optimize the iron oxide nanoparticles
for magnetic fluid hyperthermia applications. The nano‐
particle surface was functionalized with carboxymethylat‐
ed polyvinyl alcohol (CMPVA), a biodegradable, cheap,
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and hydrophilic biopolymer.[35] This process was opti‐
mized to provide higher yield, stability in biologically
relevant buffers and media, further ability for biofunction‐
alization, and allow for adjusting parameters to account for
differences in nanoparticle size. Lastly, in vitro experiments
with glioblastoma cells were conducted to highlight the
potential of the resultant stable iron oxide nanoparticles for
magnetic fluid hyperthermia.
2. Results and Discussion
2.1 Synthesis and Mechanistic Studies
Iron oxide nanoparticles were first synthesized in benzyl
alcohol under nitrogen flow. The use of nitrogen or argon
flow is often the standard method in the literature when
carrying out thermal decomposition of Fe(acac)3 or iron
carboxylate salts[24,34,44-49] This resulted in nanoparti‐
cles with a crystallite size of 5.43 ± 0.448 nm as calculated
from the powder x-ray diffraction (XRD) pattern in Figure
1 using the Scherrer equation. The saturation magnetiza‐
tion (Ms) was found to be 53.39 emu/g as measured by
vibrating sample magnetometry (VSM) and mass corrected
by thermal gravimetric analysis (TGA) data. As mentioned
previously, the optimal crystallite size for magnetic
nanoparticle-based induction heating has been shown to be
around 15 nm. While this is not the overall particle size, and
the exact relationship between particle size and heating is
not clear, our goal was to use the benzyl alcohol-based
synthesis to increase the crystallite and particle size into an
optimal range for RF heating. Thus, our hypothesis was
that the crystallite size could be increased by changing the
reaction conditions from nitrogen flow to being open to air.
Carrying out the reaction in the presence of air, A2-24,
could facilitate the oxidation of benzyl alcohol to benzal‐
dehyde and reduction of Fe(acac)3 at temperatures further
below the start of thermal decomposition, similar to the
mechanism of metal and metal oxide nanoparticle forma‐
tion in glycols.[23,50-53] Starting the reaction at lower
temperatures, where the temperature ramp rate is faster,
would allow for fewer nuclei to form and a better separa‐
tion of nucleation and growth phases; both of which would
lead to larger nanoparticles and potentially a larger
crystalline core.[15] This simple reaction parameter change
resulted in iron oxide nanoparticles with a crystallite size
of 8.33 ± 0.393 nm (Figure 1) and a Ms of 70.839 emu/g.
Typically, the thermal decomposition of Fe(acac)3 starts to
occur around 170-180°C depending on the solvent.[54]
Nanoparticle formation, indicated by a colour change from
dark red to black, initially occurred under nitrogen at
174.4°C after 31 minutes and the reaction solution appeared
completely black after 40 minutes.In contrast, carrying out
the reaction under air with identical heating rate and final
temperature (Figure S1) resulted in an initial colour change
at 169.4°C after 20 minutes and a completely black solution
at 30 minutes. This indicates that the presence of oxygen
leads to the reaction initiation occurring sooner in time and
at a lower temperature, suggesting the possibility of an
additional mechanism by which the iron oxide nanoparti‐
cles are forming in benzyl alcohol. In order to verify if the
benzyl alcohol was acting as a reducing agent in this
synthesis, FeCl2 was used as a precursor in place of the
Fe(acac)3 with the addition of NaOH as in glycol synthetic
methods.[23,51-53] This reaction produced magnetite
under both air and N2 (Figure S2) confirming the presence
of another mechanism of nanoparticle formation in benzyl
alcohol other than thermal decomposition of Fe(acac)3.As
with the Fe(acac)3 synthesis, the FeCl2 reaction under air
had an initial colour change at 90.8°C compared to 99.3°C
for N2, and turned completely black under air at 127.7°C
versus 132.7°C for the reaction under N2 (Figure S1).
Therefore, these results suggest that running the reaction
under air promotes the earlier initiation of nucleation,
giving further separation of nucleation and growth which
led to the increase in crystallite size. From this mechanistic
insight, all additional syntheses to increase size were
carried out under air.
Figure 1. XRD analysis of reactions A2-24 under N2 (blue), A2-24 (red), and
A2-24_B2-24 (green). XRD patterns are offset by 100 count increments.
2.2 Modified Seed Growth and Synthetic Parameter Effects on
Particle Size
With the goal of further increasing the crystallite size,
monodispersity and particle size for optimal RF heating, a
modified seed growth technique was investigated with
different reaction times, temperatures, precursor concen‐
trations, and multiple precursor additions. To keep track of
the reaction conditions, the following naming system was
utilized. A and B denote the first or second additions of
Fe(acac)3 respectively and are separated by an underscore.
The A and B are followed by numbers indicating the gram
amount of Fe(acac)3 added at the respective addition. This
is followed by a ‘-X’ with X indicating the time in hours the
reaction proceeded before a subsequent addition. When
temperature was investigated as a parameter, it is indicated
by the number in parenthesis beside the reaction time.
A2-24(175)_B2-24(175) for example indicates a reaction
with 2 g of Fe(acac)3 initially added to 20 mL of benzyl
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alcohol in the presence of air. This was reacted for 24 hours
at 175°C before a second addition of Fe(acac)3 which was
then reacted for 24 hours at 175°C. If a temperature is not
provided, all reactions were carried out using a heating
mantle with identical power settings confirmed by a similar
rate of reflux. These nanoparticles were characterized using
XRD, dynamic light scattering (DLS), VSM, and TGA. The
data are presented in Table 1.
The first parameter investigated to increase the crystallite
size was the initial Fe(acac)3 precursor concentration, as
some synthetic methods in the literature use this parameter
to increase the overall particle size.[55] Increasing the
Fe(acac)3 amount by 2 g per reaction, (A2-24, A4-24 and
A6-24) resulted in no significant change in crystallite size.
This did however show an increase in the hydrodynamic
diameter of 13.64 nm, 14.68 nm and 16.5 nm and polydis‐
persity index (PDI) values of 0.703, 0.2 and 0.164 respec‐
tively (note: a lower PDI corresponds to a more
monodisperse solution). The increase in overall particle
size and decrease in PDI can be rationalized by the LaMer
growth model.[56-58] Increasing the Fe precursor concen‐
tration leads to an increased rate of reaching the critical
supersaturation concentration for nucleation and the
critical limiting supersaturation level.[56,58] Upon reach‐
ing this critical supersaturation, a ‘burst’ nucleation event
occurs, depleting the concentration of monomers for
nucleation below the critical supersaturation limit and thus
halting further nucleation.[56,58] Then, the reaction
switches over to growth, with the remaining monomers in
solution then growing on the nuclei by diffusion.[56,58]
This provides a better separation of the nucleation and
growth phases to increase the monodispersity and more
available material for the growth phase leading to larger











A2-24 70.839 0.170 8.1 13.64 0.703
A2-24(175) 70.91 0.142 9.1 12.45 0.61
A2-24(195) 74.322 0.175 7.8 13.3 0.65
A4-24 68.99 0.134 8.3 14.68 0.2
A6-24 68.25 0.219 7.9 16.5 0.164
A2-24_B2-24 75.7 2.536 12.8 28.93 0.148
A2-24_B2[cool addition]-24 72.488 0.670 9.6 20.76 0.252
A2-24(175)_B2-24(175) 77.89 1.004 11.4 24.53 0.404
A2-24(185)_B2-24(185) 77.249 1.068 13.2 23.11 0.395
A2-24(195)_B2-24(195) 78.202 4.041 15.2 37.52 0.219
A2-2 60.6 0.032 6.3 10.93 0.311
A2-2_B2-2 62.85 0.069 5.9 17.88 0.447
A2-2_B2-24 76.1 0.211 9.2 20.07 0.373
A2-2_B4-2 62.8 0.102 8 15.43 0.258
A2-2_B4-24 72.18 0.212 9.4 17.72 0.304
A2-2_B6-24 75.56 0.639 11.1 19.42 0.368
a)Mass unit indicates grams of iron oxide nanoparticles corrected by TGA.
b)Mass unit indicates milligrams of Fe determined by Prussian blue assay.
c)Polydispersity Index (PDI) determined by DLS.
Table 1. Saturation Magnetization, Heating Profile, and Average Size determined by VSM, Heating Induction, XRD, and DLS.
The next parameter that was altered was reaction time, to
determine its effect on the resultant particle characteristics.
A time of 2 hours was chosen to give a significantly shorter
reaction as compared to 24 hours, while ensuring that the
reaction had ample time to turn completely black, which
would indicate a majority of the precursor had been
consumed. As seen in Table 1, A2-2 resulted in a smaller
crystallite size and a lower Ms of 60.6 emu/g as compared
to A2-24.However, the PDI was significantly reduced
under these conditions. Thus, it was thought that this level
of monodispersity would provide adequate seeds to use a
modified seed growth synthesis to increase the crystallite
size. The primary difference between traditional seed
growth processes and the modification reported here is in
the addition step. Traditional methods involve cooling or
aging the nanoparticles, followed by washing in organic
solvents and drying to a powder to produce the seeds.
[59-61] These seeds are then redispersed in their solvent
and more iron precursor is added before the temperature
is increased back to the reaction conditions. In this modified
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seed growth the addition of more Fe precursor is performed
at the ‘hot’ reaction temperatures, and thus the nanoparti‐
cles stay dispersed and remain at temperatures suitable for
nucleation and growth. Using a second addition with a 2-
hour reaction time, A2-2_B2-2, did produce nanoparticles
with an increase in overall size (DLS data Table 1), but this
did not increase the crystallite size. As discussed above, the
Fe precursor concentration and short reaction time provid‐
ed lower PDI, while the 24-hour step provided a larger
crystallite and increased Ms. Therefore, a series of modified
seed growth syntheses were conducted with various
combinations of Fe(acac)3 concentration and reaction time
at the first and second additions (data in Table 1).Keeping
the first addition constant at 2 g for two hours, it was found
that a 24-hour step was critical for achieving a larger
crystallite size and higher Ms. The sample from this series
with the highest crystallite size of 11.1 nm was
A2-2_B6-24.Since this was still under our goal of 15 nm, a
seed growth with two 24-hour reaction times was attempt‐
ed to possibly begin with seeds of a larger crystallite size.
The ‘hot’ addition would then allow for continued crystal‐
lite growth instead of just particle growth.A2-24_B2-24 not
only resulted in an increased crystallite size of 12.8 nm, but
also a decreased PDI of 0.148.A representative transmission
electron microscopy (TEM) image of A2-24_B2-24 nano‐
particles is shown in Figure S3. This increase in monodis‐
persity is speculated to be due to the ‘hot’ addition,
providing an initial burst nucleation of small nuclei which
are subsequently dissolved and grow on the larger seeds
already present in solution, in agreement with ‘Ostwald
ripening’.[62,63] Additionally, this mechanism of growth
can increase the monodispersity of nanoparticles formed.
[64] To corroborate this ‘hot’ addition mechanism, a similar
reaction was cooled to 30°C before the second addition of
iron precursor, A2-24_B2(30)-24. This resulted in nanopar‐
ticles with a smaller crystallite size of 9.6 nm and an
increased PDI of 0.252, which suggests that the ‘hot’
addition does indeed facilitate the continued crystallite
growth and is an important parameter of this synthesis.
The last parameter investigated was reaction temperature.
Using a silicon oil bath for precise temperature control, the
reaction temperature was varied for the modified seed
growth reactions A2-24(175)_B2-24(175),
A2-24(185)_B2-24(185) and A2-24(195)_B2-24(195) (Table
1). A2-24(175)_B2-24(175) resulted in a crystallite size of
11.4 nm with a PDI of 0.404. Raising the temperature to
185°C and 195°C was hypothesized to increase the crystal‐
lite size and lower the PDI promoting the Ostwald ripening
process and providing better separation of nucleation and
growth. Indeed, the crystallite size increased to 13.2 nm for
A2-24(185)_B2-24(185), and further increased to 15.2 nm for
A2-24(195)_B2-24(195).The 195°C reaction also yielded the
highest overall particle size and lowest PDI of 0.219 for the
temperature series with two additions. Interestingly, a
temperature effect was not seen when running only one 24-
hour reaction with samples A2-24(175) and A2-24(195),
evidenced by no significant change in crystallite size (Table
1). This could indicate that the initial reaction step is
governed by LaMer growth, being more dependent on
concentrations, with the second addition being dominated
by Ostwald ripening and leading to more monodispersed
nanoparticles. While future studies are necessary to
elucidate this point, the parameters studied here provide a
range of iron oxide nanoparticles that were examined for
RF heating applications.
2.3 Radiofrequency Induction Heating Characterization and
Assessment
Initial radiofrequency (RF) heating experiments were used
to characterize the ability of the iron oxide nanoparticles to
heat in solution. For these studies, the nanoparticles were
dispersed in a constant volume of 0.25% tetramethylam‐
monium hydroxide (TMAOH) aqueous solution and
placed in the AC magnetic field with a magnetic field
strength (H) of 37.4 kA/m and a frequency (f) of 270 kHz.RF
heating curves of solutions were measured by a fibre optic
temperature probe and are shown for deionized water,
A2-24 under N2, A2-24, A2-24_B2-24, and
A2-24(195)_B2-24(195) in Figure 2.
Figure 2. Heating curves of 3 mL of water and iron oxide samples dispersed
in 0.25% TMAOH. Concentrations of iron determined by Prussian Blue UV-
VIS are 0, 14.48, 15.40, 14.00, and 15.36 mg/mL for deionized water (blue),
A2-24 under N2 (green), A2-24 (red), A2-24_B2-24 (purple), and
A2-24(195)_B2-24(195) (black) respectively. An alternating magnetic field
175.4 A at frequency of 270 kHz for 600 seconds was used, and the
temperature was recorded every 1.4 seconds.
For comparison between samples, the initial heating rate
was calculated from the linear portion of the heating
curve.While the mass of iron oxide particles used for each
solution was constant, the heating rates were corrected by
a Prussian blue assay for the concentration of Fe (Table 1).
Compiling all of the data in Table 1, there are several
conclusions to be drawn from the relationship between RF
heating rate, particle characteristics, and synthetic param‐
eters. First, nanoparticles produced without a 24-hour
reaction step all resulted in Ms values between 60-65
emu/g as shown in Figure 3A,C,E (red squares). Upon
incorporating a 24-hour step, whether at each addition or
only the second addition (e.g., A2-2_B2-24), the Ms
increased to 72-78 emu/g (Figure 3A,C,E – green triangles).
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While the Ms also showed a positive correlation with
crystallite size (Figure 3A) and hydrodynamic diameter
(Figure 3C), there was no clear correlation between RF
heating and Ms (Figure 3E).Next, in agreement with the
literature, there was a strong correlation between RF
heating and crystallite size with a sharp increase as the
crystallite size approaches 15 nm (Figure 3B).The data also
show a correlation between the RF heating and hydrody‐
namic diameter (Figure 3D).
Figure 3. Comparison of syntheses conducted under nitrogen flow (blue), open to air with total reaction times less than six hours (red), and open to air with
reactions involving at least one 24-hour reaction step (green). (A, B) Plots of crystallite size versus Ms and RF heating. (C, D) Plots of hydrodynamic diameter
versus Ms and RF heating. (E) Plot showing Ms versus RF heating. (F) Plot of polydispersity index versus RF heating.
While this could be primarily due to the linear correlation
between crystallite size and hydrodynamic diameter
(Figure S4), it could also suggest that there is an optimal
hydrodynamic diameter to provide maximal heat exchange
between the particle and the surrounding environment.
Further studies will be needed to determine this contribu‐
tion. Lastly, there is an overall negative correlation between
RF heating and PDI, which indicatesthat a system that is
more monodispersed has improved heating.However,
particle size (both crystallite and hydrodynamic diameter)
appears to be the dominant determining factor in optimal
RF heating for iron oxide nanoparticles. From the syntheses
above, the A2-24_B2-24 synthesis was used for functional‐
ization investigation and in vitro studies due to its high RF
heating profile (~2.5[°C/min] /g) and high level of mono‐
dispersity (PDI – 0.148), which can enhance overall post-
functionalization colloidal stability.
2.4 Surface Functionalization and Optimization for Biostability
Modifying the surface of iron oxide nanoparticles is
essential for biostability and further conjugation. CMPVA
can be attached to the surface of iron oxide through strong
interactions with the carboxyl groups.[49] Carboxyl groups
not involved in attaching to the surface can be used for
further conjugation by reactions such as EDC coupling.
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CMPVA was produced through carboxymethylation of
polyvinyl alcohol [35] and confirmed by Fourier transform
infrared (FTIR) spectroscopy (Figure S5). Previous report‐
ed methods for functionalizing the surface ofiron oxide
particles with CMPVA required an organic to aqueous
phase transfer process using chloroform and 1.5% TMAOH
solution.[35] In the studies reported here, the dried
particles as prepared in benzyl alcohol were easily dis‐
persed in a TMAOH solution directly and required no
opposing phase transfer to remove other capping agents.
First attempts for CMPVA functionalization using the
previously reported methods proved unsuccessful in
obtaining iron oxide nanoparticles with long-term stability
in biologically relevant medium (PBS, tissue culture
medium, etc.). There could be several factors influencing
the particle functionalization efficiency by CMPVA (e.g.,
particle size, TMAOH concentration, pH, CMPVA concen‐
tration, etc.), which the previous work had optimized for
their specific material and particle size.[35] Therefore,
modifications were made to the surface functionalization
process and parameters were investigated to optimize the
yield and overall stability of the functionalized iron oxide
nanoparticles.
Iron oxide nanoparticles were dispersed at a concentration
of 20 mg/mL in 0.0625%, 0.125%, 0.25%, and 0.5% w/w
TMAOH and mixed with a constant CMPVA concentration
of 20 mg/mL (40:1 CMPVA to iron oxide mass ratio).The
initial TMAOH concentration is important in ensuring a
stable dispersion of iron oxide nanoparticles prior to
mixing with CMPVA. Initial DLS analysis of A2-24_B2-24
dispersed in the various concentrations of TMAOH
showed consistent hydrodynamic diameters with a mean
of 26.42 ± 1.31 nm (Table S1). In order to analyse the effect
of the initial TMAOH percentage on functionalization, DLS
was performed at each step of the process and the results
are shown in Figure 4. Upon addition of the CMPVA
solution, the 0.0625% TMAOH nanoparticle solution
became turbid and had a substantial amount of aggregation
and precipitation indicated by a PDI value of 0.51 and
greater than 95% of the population of particles having an
average hydrodynamic diameter over 1000 nm (Figure
4A).This was seen for each step of the functionalization and
buffer exchange process. Nanoparticles dispersed in the
three higher TMAOH percentages had no aggregation
occurring in steps 1 and 2.Since the initial nanoparticle
solution was stable, the addition of CMPVA to the 0.0625%
TMAOH could lower the pH below what is suitable for
colloidal stability of iron oxide nanoparticles. Solutions of
CMPVA alone and CMPVA with iron oxide nanoparticles
at concentrations identical to reaction conditions were
titrated with 6.25% TMAOH (Figure S6). While the pH of
the CMPVA alone was at an adequate level for stability
throughout the titration curve (8.5 or greater), the addition
of iron oxide nanoparticles lowered the pH from 8.68 to
6.89.It was found that a minimum TMAOH concentration
of 0.125% was required to reach a pH of 8.5 or greater and
keep the nanoparticles dispersed throughout the function‐
alization with CMPVA. At the highest TMAOH concentra‐
tion used (0.5%), the iron oxide nanoparticles appeared to
have exchanged TMAOH for CMPVA, as seen in Figure 4D
steps 1 and 2.However, upon thorough removal of
TMAOH and buffer exchange with a PD-10 desalting
column (Figure 4D steps 3 and 4) greater than 90% of the
population of particles aggregated with an average
hydrodynamic diameter over 1000 nm. Furthermore, large
amounts of nanoparticles were left on the PD-10 column,
indicating a lack of stability as the TMAOH was being
removed.T his can be explained by inadequate exchange of
TMAOH for CMPVA due to a higher concentration
gradient keeping the TMAOH on the iron oxide surface.
Nanoparticles that remained on the column are thought to
have been only stabilized by the presence of TMAOH and
thus aggregate and precipitate during the buffer exchange
process. Additionally, corroborating evidence for this was
seen for nanoparticles in TMAOH solution without
CMPVA surface functionalization, which were completely
retained on the PD-10 during buffer exchange. Then, as
indicated by the DLS data, the populations of nanoparticles
with a smaller hydrodynamic diameter are speculated to
be functionalized with less CMPVA. These populations of
nanoparticles were labelled as ‘inadequately functional‐
ized’ because eluted samples containing this smaller
population eventually had some degree of aggregation and
a loss of colloidal stability. Therefore, the functionalization
was inadequate for long-term stability. It is speculated that
the inadequately functionalized nanoparticles aggregate
over time due to bridging between nanoparticles at surface
regions made available for carboxyl linkage upon removal
of the TMAOH. Until the TMAOH was thoroughly
removed, this was not apparent, and thus the PD-10
desalting column is an essential clean-up step to improve
long-term stability and isolate the stably functionalized
population. The two intermediate TMAOH concentrations
used both proved successful in functionalizing the iron
oxide nanoparticles with CMPVA. The primary difference
was seen in step 3, which had a 20% population that was
inadequately functionalized for the 0.25% TMAOH (Figure
4C). The re-emergence of inadequately functionalized
nanoparticles in this step suggests that the TMAOH
concentration was slightly too high for optimal CMPVA
exchange. At the 0.125% level, steps 1 and 2 had around a
50:50 population of functionalized and inadequately
functionalized nanoparticles (Figure 4B). After steps 3 and
4, the entire population of nanoparticles was functional‐
ized. While both 0.125% and 0.25% TMAOH resulted in
functionalized nanoparticles with low PDI values (0.169
and 0.163 respectively) in the final product, the 0.125% had
a larger population of functionalized nanoparticles initially
(step 1) and thus a higher overall yield. Therefore, 0.125%
was determined to be the optimal of the four tested
concentrations of TMAOH for surface functionalization
with CMPVA.
7Stanley E. Gilliland III, Everett E. Carpenter and Michael D. Shultz:
Modified Seed Growth of Iron Oxide Nanoparticles in Benzyl Alcohol – Optimization for Heating and Broad Stability in Biomedical
Applications
Figure 4. The effect of various concentrations of TMAOH on surface functionalization efficiency of CMPVA. Iron oxide nanoparticles are labelled as either
functionalized (blue), inadequately functionalized (red), or aggregated (green) based on their hydrodynamic size (data labels). (A) 0.0625% TMAOH, (B)
0.125% TMAOH, (C) 0.25% TMAOH, and (D) 0.5% TMAOH at several steps in the surface functionalization clean-up process. Step 1 and 2 are before and after
the 30k MWCO centrifugal filter. Step 3 and 4 are fractions 1 and 2 of elution from a PD-10 desalting column.
Next, it was important to test whether or not the above
conditions would work with different size nanoparticles.
The largest nanoparticles synthesized were
A2-24(195)_B2-24(195) with a crystallite size of 15.2 nm and
a hydrodynamic diameter of 37.5 nm compared to 12.8 nm
and 28.9 nm respectively for the A2-24_B2-24 particles.
They were first functionalized under the same optimal
conditions determined above (0.125% TMAOH, 20mg/mL
CMPVA and the same mass ratio of CMPVA to nanoparti‐
cles). This resulted in nanoparticles that were functional‐
ized with CMPVA, but with hydrodynamic diameters
larger than desired (average 310.97 ± 51 nm) which resulted
in aggregation and precipitation of the final product. Since
there was an adequate amount of TMAOH present to keep
the nanoparticles stable for CMPVA functionalizing, it was
thought that the concentration of CMPVA was too high,
causing more crosslinking between particles and leading to
larger hydrodynamic diameters. At the same mass, the
smaller nanoparticles would have both a higher total
surface area and there would be a higher total number of
nanoparticles. Therefore, calculations were performed to
determine an approximate ratio between the number of
CMPVA molecules and both the number of iron oxide
nanoparticles and total nanoparticle surface area used in
the previous successful functionalization. To simplify
calculations of the volume and surface area, the equations
for a sphere were used, since TEM analysis revealed a
spherical morphology. Calculations were first performed
using the diameter determined by the crystallite size (12.8
or 15.2 nm) as measured by XRD and performed using the
hydrodynamic diameter (28.9 and 37.5 nm) as measured by
DLS.Next, the number of particles in 10 mg was estimated
using the calculated volume and density of iron oxide
(Fe3O4 – 5.17 g/cm3). The number of particles was then used
to calculate the total surface area of 10 mg of nanoparticles.
A total of 400 mg of CMPVA was used originally to surface
functionalize the 12.8 nm crystallite nanoparticles. Thus,
400 mg was converted to an approximate number of
CMPVA polymer molecules using the molecular weight of
PVA (6000 g/mol) and Avogadro’s number. Then, the
number of CMPVA molecules per number of nanoparticles
or total surface area in 10 mg was calculated and converted
to a required concentration to match the original ratio of
CMPVA to nanoparticles or total surface area for the
A2-24_B2-24 sample. In this regard, using the increase in
crystallite size from 12.8 to 15.2 nm yielded a required
concentration of 12.4 mg/mL, and using the increase in
hydrodynamic diameter from 28.9 to 37.5 nm yielded a
required concentration of 10.7 mg/mL. In relation to surface
area, the required concentrations were 17.1 mg/mL and 16.2
mg/mL, respectively. These values were averaged in the
following results as the effect of the relative size increases
were in close agreement. It was determined that the optimal
conditions contained 2.28×104 CMPVA molecules for every
one nanoparticle and a ratio of CMPVA molecules to total
nanoparticle surface area of 4.43×1019.Using these values to
adjust for the lower number of nanoparticles and surface
area when using the same mass of the larger nanoparticles,
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A2-24(195)_B2-24(195), two functionalization attempts
were conducted at 11.5 mg/mL and 16.7 mg/mL instead of
the previous 20 mg/mL. The functionalization reaction
matched for the number of nanoparticles (11.6 mg/mL)
resulted in functionalized nanoparticles with a PDI of 0.206
and with an average hydrodynamic size of 199.97 ±
34.04nm (50%) and 54.79 ± 24.53 nm (50%) (Figure S7).
While these numbers suggest that there is a split in volume
percentage of larger clusters and smaller clusters function‐
alized with CMPVA, they are, as expected, slightly larger
than the values in Figure 4, and remained stable in various
media. The reaction based on total surface area resulted in
the majority of particles having a hydrodynamic diameter
approaching 1000 nm, indicating aggregation and cross-
linking. It is therefore apparent that when functionalizing
different sizes of nanoparticles the concentration of
CMPVA should be adjusted to account for the number of
CMPVA molecules relative to the number of nanoparticles.
2.5 In vitro Studies
With the optimal nanoparticle and surface functionaliza‐
tion methods for stability, some initial pilot experiments
were conducted to verify that the nanoparticles could be
used to deliver hyperthermia doses to kill glioblastoma
tumour cells.For these in vitro studies, the functionalized
product of A2-24_B2-24 was chosen based on its high RF
heating profile (~2.5[°C/min] /g) and high level of mono‐
dispersity.M059K cells were either treated with PBS or iron
oxide nanoparticles for 24 hours. Studies have shown that
nanoparticles are taken up by cancer cells through various
mechanisms, such as endocytosis, electrostatic interactions,
or phagocytosis.[65-67] When harvested, the cells were
washed thoroughly with PBS and placed in fresh medium
to provide one group without any nanoparticles (no
particle control group – blue) and one group ‘loaded’ with
iron oxide nanoparticles either surface bound or internal‐
ized (particle group – red). Based on cellular uptake studies
(Figure S8), this group had roughly 0.2 µg of Fe per 100,000
cells. A third group was prepared by taking particle treated
cells and adding medium that was loaded with iron oxide
nanoparticles (extra particle group – green) at a concentra‐
tion that would produce measureable heating of the cell
suspension. With the additional ~325 µg of Feloaded in the
medium, this group had 99.94% of the iron oxide nanopar‐
ticles ‘external’ and 0.06% (0.2 µg/325.2 µg) ‘internal’. Thus,
the particle treated group could be considered ‘internal’
heating and the extra particle group will have both ‘inter‐
nal’ and ‘external’ heating, with the ‘external’ heating being
dominant.[65,66]
Firstly, as can be seen in Figure 5 (top), the M059K cells that
were not exposed to the RF heating showed no significant
change in survival between the three treatment groups,
indicating that the two iron oxide nanoparticle treatments
did not have a significant toxicity alone (see Table S2, S3,
and S4 for statistical analysis results).Next, the cells without
iron oxide nanoparticles showed no change in survival
while being exposed to the RF AC magnetic field for ten
and 15 minutes. Furthermore, the temperature profile of
the cell suspension during the ten and 15 minute RF
treatment in Figure 5 (bottom, blue line) showed little
deviation from 37°C.However, RF treatment of both iron
oxide nanoparticle treated groups showed a significant
decrease in cell survival at ten minutes. While this is the
expected result for hyperthermia treatment, the interesting
aspect can be seen when comparing the cell suspension
temperature profiles (Figure 5 – bottom).The cell suspen‐
sion of the particle treated group (red line) only reached
38.5°C at ten minutes but showed similar cell killing to the
extra particle group (green line) that reached 47.1°C. Then,
at 15 minutes, both particle treated groups also showed
significantly more cell killing compared to the control
group (no particle – 0 min).Although at 15 minutes the extra
particle group reached thermal ablation range at 48.4°C
compared to just 39.1°C for the particle group and appears
to have more cell killing, pairwise comparison of the means
(ANOVA – Tukey HSD post hoc test – see Table S5) was
not significant. Further experimental replicates (higher N)
may reveal a significant difference between these groups,
which would be expected due to the greatly different
external temperatures reached. These initial results
demonstrate that tumour cells can be treated with iron
oxide nanoparticles sufficiently to provide hyperthermia
effects upon RF heating treatment. They also suggest a
Figure 5. Effect of RF heating (H=42.7 kA/m at f=200.2 A) on M059K cell
survival. (Top) The survival of M059K cells treated with either no particles
(blue), particles (red), or extra particles (green) and subjected to RF heating
for 0, 10, or 15 minutes. The * indicates groups significantly different from
the control, as determined by ANOVA and Dunnett two-sided post hoc test
at a 0.05 significance level. (Bottom) The respective heating curves for no
particles (blue), particles (red), and extra particles (green). Dashed line
indicates ten and 15 minutes of heating.
9Stanley E. Gilliland III, Everett E. Carpenter and Michael D. Shultz:
Modified Seed Growth of Iron Oxide Nanoparticles in Benzyl Alcohol – Optimization for Heating and Broad Stability in Biomedical
Applications
potential difference between the ‘internal’ and ‘external’
heating modes, which needs to be investigated further to
elucidate the benefits and mechanism of cell death in‐
volved.
3. Conclusion
Iron oxide nanoparticles were successfully produced at a
variety of sizes by use of a modified seed growth approach
requiring just the iron precursor and solvent, and only one
subsequent hot addition of precursor without intermediate
wash steps. With the parameters investigated, it appears
that combining factors that influence the LaMer model for
growth with other factors that drive the Ostwald ripening
model may lead to further size control and monodispersity
with the benzyl alcohol synthesis system. While the RF
heating investigation revealed increased heating, as
expected while approaching the 15 nm crystallite, further
studies will strive to increase the crystallinity of iron oxide
nanoparticles without large changes in the overall particle
size. This will provide a more comprehensive answer to the
optimal combination of crystallite and particle size for RF
induction heating applications. The surface functionaliza‐
tion optimization yielded both a better understanding of
the impact of the TMAOH concentration, and the ability to
tune the CMPVA concentration for stabilizing different
sizes of iron oxide nanoparticles for biological applications.
The CMPVA functionalized iron oxide nanoparticles
produced under these conditions were stable for longer
than six months. Future studies of CMPVA surface func‐
tionalization will aim to further optimize the amount of
time required for adequate surface functionalization and
probe for possible effects on nanoparticle stability due to
shortening or prolonging the surface functionalization
step. Then, the in vitro studies, in total, suggest two
possibilities that need to be investigated further. First, the
comparable cell killing at largely different temperatures
could indicate a difference in the mechanism of cell death
for internal versus external heating modes. This could lead
to other therapies having a synergistic interaction with the
internal nanoparticle delivered hyperthermia that are not
currently known to interact with traditional hyperthermia.
Furthermore, the ability to kill tumour cells without a
significant increase in the temperature of the surrounding
environment or tissue could make the nanoparticle-
delivered hyperthermia more viable for treating difficult
cancers like glioblastoma, while limiting the risk of normal
tissue damage. These two points will need to be investigat‐
ed fully to further aid translation into the clinical setting.
4. Experimental Section
4.1 Synthesis of Iron Oxide Nanoparticles
All chemicals and materials were used as received. Iron
oxide nanoparticles were synthesized under nitrogen flow
or open to air in a two-neck 100 mL round bottom flask
(Chemglass) equipped with a coil style reflux condenser
(Chemglass). First, iron (III) acetylacetonate (Fe(acac)3) (2,
4, or 6 g) (Acros Organics, 99+%) was dissolved in benzyl
alcohol (20 mL) (Alfa Aesar, 99%) under constant magnetic
stirring. The solution was stirred vigorously and immedi‐
ately heated to reflux. Upon colour change from dark red
to black, the reactions were carried out for two or 24 hours.
The reaction was removed from heat and stirred for 15
minutes to allow for cooling. The resultant iron oxide
nanoparticles were precipitated in acetone (Fisher Scientif‐
ic, ACS grade) and extracted by magnetic separation.
Washing with acetone was repeated 3-5 times with brief
sonication (Cole Parmer, Ultrasonic Cleaner 8892) between
washes. Flowing nitrogen was used to dry the nanoparticle
product to a fine powder.
For the modified seed growth procedures, Fe(acac)3 (2 g)
was dissolved in benzyl alcohol (20 mL) in a round bottom
flask under a coil style reflux condenser, stirred vigorously,
and heated to reflux, as described above. At two or 24 hours
of reaction time a second addition of Fe(acac)3 (2, 4, or 6 g)
was added, as a solid powder, directly to the hot reaction
and continued to react for two or 24 hours.For reactions
where precise control of temperature was required, the
heating mantle (Thermoscientific, electrothermal heating
mantle) was replaced with a silicon oil bath (Alfa Aesar)
and temperature controlled by the magnetic stirring hot
plate (VWR, VMS-C7) equipped with a temperature control
unit (VWR, VT-5 S40). To determine important tempera‐
ture thresholds, the temperature and colour of the solution
was monitored and recorded every minute until reaching
the desired reaction temperature and the solution colour
changed completely to black, indicating high levels of
nanoparticle formation. Reactions were heated at the
highest ramp rate obtainable by the heating mantle or hot
plate and oil bath. Products from the seed growth were
cooled and washed under the same conditions as all other
reactions listed above.
4.2 Synthesis of Carboxymethylated Polyvinyl Alcohol
(CMPVA)
CMPVA was synthesized by reacting polyvinyl alcohol
(PVA) (Polysciences Inc., MW 6000, 80 mol% hydrolysed)
with bromoacetic acid (Alfa Aesar, 98+%) in the presence
of base as previously described.[35] First, three solutions
were made as follows: Solution A - PVA (5 g) dissolved in
H2O (50 mL), Solution B - sodium hydroxide (NaOH)
(5.324 g) (Alfa Aesar, pearl, 97%) dissolved in H2O (25 mL),
and Solution C bromoacetic acid (11.575 g) dissolved in 70%
ethanol (EtOH) (200 mL) (Sigma Aldrich, 200 proof for
molecular biology).Next, NaOH (3.33 g) was slowly
dissolved in Solution C. Solution B was added to Solution
A slowly under constant stirring at 50°C. This was followed
by drop wise addition of Solution C and reacted under a
reflux condenser at 50°C for five hours to carboxymethylate
the PVA. The pH of the synthesized CMPVA was adjusted
to ~6.0 with hydrochloric acid (HCl) (1 M) (Fisher Scientific,
Optima) and precipitated with cold EtOH (Pharmco-
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AAPER, 190 proof ACS/USP grade). CMPVA product was
centrifuged at 3000×g for 15 minutes (Thermo Scientific,
Sorvall Legend X1R centrifuge) and washed 3-6 times with
EtOH. The CMPVA was then dried in a vacuum oven at
50°C for one week.
4.3 Surface Functionalization of Iron Oxide Nanoparticles with
CMPVA
First, dry iron oxide nanoparticles (40 mg) were dispersed
in aqueous solutions of tetramethylammonium hydroxide
(TMAOH) (Alfa Aesar, 25% w/w aqueous electronic grade
99.9999%) (2 mL; 0.0625%, 0.125%, 0.25%, or 0.5% w/w). The
solution was not magnetically stirred at any point in the
functionalization process, in order to limit any aggregation
from magnetic fields that might occur. The nanoparticle
solution was sonicated for 180 minutes and allowed to sit
overnight. Then, the nanoparticle solution (0.5 mL) was
added to a mixture of CMPVA (10 mL, 40 mg/mL) and
H2O (9.5 mL). Subsequently the solution was sonicated for
180 minutes and allowed to sit for one week. One week was
chosen for this work as initial functionalization studies
were carried out and observed for two weeks. During this
two-week time frame, the particles remained slightly
turbid after 24-48 hours, but were visibly clear after one
week of reaction. The solution was then centrifuged in a
30K molecular weight cut-off centrifugal filter (PALL,
Macrosep® Advance Device) at 4000×g for one hour to
concentrate the nanoparticles and remove excess CMPVA.
The concentrated nanoparticle solution was transferred to
a new vial and sonicated for 15 minutes to ensure complete
redispersion. Next, the CMPVA functionalized iron oxide
nanoparticle solution was loaded on to a PD-10 desalting
column (GE Healthcare, Sephadex® G-25 medium),
equilibrated with H2O (Fisher Scientific, Optima ® LC/MS
grade) to remove any remaining TMAOH and non-
functionalized or aggregated nanoparticles. This was
followed by an additional concentration step using the
same 30K centrifugal filter as above spinning at 4000×g for
one hour and sterile filtering using a 0.2 µm sterile filter
(PALL, Acrodisc® Supor® membrane) in a biosafety
laminar flow hood. The resulting sterile nanoparticles were
stable in water and PBS.
4.4 Characterization
4.4.1 X-ray Diffraction
Powder x-ray diffraction (XRD) patterns were obtained on
a PANalyticalX'Pert Pro Materials Research Diffractome‐
ter. Dried samples (~300 mg) were mildly ground to obtain
a fine powder. The fine powder was transferred to a low
background silicon disk. XRD patterns were scanned at
20-80° 2θ using a Cu Kα x-ray source and evaluated using
X’Pert High Score Plus software. The Scherer equation was
used to calculate the crystallite size from peak broadening
of diffraction peaks.
4.4.2 Dynamic Light Scattering
The hydrodynamic diameters and polydispersity indexes
of iron oxide nanoparticles were analysed at ambient
conditions using a Malvern ZetasizerNano-ZS (Malvern
Instruments, U.K.). The DLS light source used was a He-Ne
laser (633 nm, max 4 mW). Iron oxide nanoparticles (20 mg/
mL) were dispersed in TMAOH solution (0.25%) and
sonicated for 180 minutes. After sitting overnight a 1:100
dilution (1 mL) was made for DLS analysis. Samples were
then transferred to a low volume disposable cuvette and
hydrodynamic diameter and PDI values were calculated as
an average of five runs containing 11 measurements per
run.
4.4.3 Vibrating Scanning Magnetometry
Magnetic characteristics were probed using a VersaLab 3
Tesla Cryogen-Free Vibrating Sample Magnetometer
(VSM) (Quantum Design). Samples were prepared by
weighing dry samples (5-15 mg) and sealing in a sample
capsule (Quantum Design). VSM sample capsules were
loaded and scanned for offset at 35 mm. Moment versus
field measurements were conducted at <50 Torr purged
pressure, a sweep rate of 150 Oersted/second (Oe/s) with
no automatic centring and scanning five quadrants from 0
Oe to 15,000 Oe (Hmax) to -15,000 Oe (Hmin). Saturation
magnetization was determined from the magnetization
versus magnetic field strength plots at Hmax or Hmin.
Samples were mass corrected with thermogravimetric
analysis (TGA).
4.4.4 Thermogravimetric Analysis
To determine mass corrected values, thermogravimetric
analysis (TGA) was run on a Q5000 TGA (TA Instruments).
Dry samples (5-50 mg) were loaded onto platinum pans
and the temperature was ramped at 10°C/min from room
temperature to 150°C and held isothermal for 15 minutes.
Subsequently, ramping was continued at 10°C/min to
400°C and held isothermal for 60 minutes. TGA was run
under a nitrogen flow rate of 25 mL/min.
4.4.5 Transmission Electron Microscopy
Brightfield transmission electron microscopy (TEM)
images of iron oxide nanoparticles were obtained with a
Zeiss LIBRA® 120 PLUS TEM. Samples were prepared for
TEM by drying 1:10 dilution of iron oxide nanoparticles in
0.25% TMAOH solution (2 mL; 20 mg/mL) on copper TEM
grids (Ted Pella Inc., 200 mesh Formvar carbon type B).
Images of CMPVA functionalized iron oxide nanoparticles
were loaded at a 1:10 dilution after all clean up and filtering
processes described above. Nanoparticle size measure‐
ments were performed using Image J software.
4.4.6 Fourier Transform Infrared Spectroscopy
Successful synthesis of CMPVA was determined by Fourier
transform infrared (FTIR) spectroscopy using Thermo
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Scientific Nicolet 6700 equipped with a smart iTR for
attenuated total reflectance (ATR) of samples. Dry CMPVA
and PVA samples were pressed onto the diamond crystal
and analysed using single bounce ATR.
4.5 Radio Frequency Heating Experiment
The heating properties of iron oxide nanoparticles synthe‐
sized by different parameters were investigated using
1.2-2.4 kW EasyHeat induction heating system with a coil
designed at a setpoint of 200 A to run at 1222 W and
frequency (f) of 269 kHz to produce an alternating magnetic
field with a magnetic field strength (H) of 37.4 kA/m at 175.4
A. The temperature of the solution being exposed to the RF
AC magnetic field was measured in situ with an OpSens‐
fibre optic temperature sensor and recorded by SoftSens
software. Initial tests were performed on iron oxide
nanoparticles in 0.25% TMAOH aqueous solution (3 mL; 20
mg/mL). The RF heating was conducted at 175.4 A, and
H=37.4 kA/m for 600 seconds and the temperature was
recorded every 1.4 seconds. To account for convection
heating, water (3 mL) was measured under the same
conditions. The temperature rise was constant over the
entire 600 seconds with a dT/dt value of 0.549°C. This value
was used to correct the initial linear temperature rise of RF
heating of iron oxide TMAOH samples. RF heating values
are corrected for the concentration of iron as determined by
Prussian Blue assay. A standard curve was produced by
Prussian Blue UV-Vis absorption assay (λ=715 nm) with a
Fe ICP standard (Alfa Aesar, Iron, plasma standard
solution, Specpure®, Fe 1000 µg/mL) and UV-Vis absorp‐
tion with a Nanodrop 2000c spectrometer (Thermo Scien‐
tific).The RF heating samples were first diluted 1:100. Then,
the samples (10 µL) were mixed with HCl (10 µL; 2%)
(Electron Microscopy Sciences) and Prussian Blue (20 µL;
2%) (Electron Microscopy Sciences). After exactly 15
minutes of incubation at room temperature UV-Vis
absorption of prepared samples (2 µL) was measured with
no baseline correction. This same method was used to
assess the cellular uptake for the CMPVA functionalized
iron oxide nanoparticles used in the cell survival studies.
Medium samples were prepared for concentration assess‐
ment similar to the above solutions. Cell pellets were
collected and subjected to lysis buffer (Sigma Aldrich,
CelLytic M) prior to preparation for Prussian Blue addition,
in order to release the nanoparticles into solution. Further
details are provided in Supporting Information.
The solution of CMPVA functionalized iron oxide nano‐
particles (650 µL) was tested to determine optimum heating
power and time for cell survival experiments. The solution
of iron oxide nanoparticles at 37°C were heated at 200.2 A
and 230.4 A for 1200 seconds to determine which temper‐
atures were reached over time. Heating at 200.2 A
(H=42.7kA/m, f=270 kHz) for 1200 seconds resulted in
reaching temperatures in the moderate hyperthermia
range. To ensure that heating occurs mainly due to cou‐
pling to the alternating magnetic field and not convective
heat flow from the coil cell media, 650 µL was heated in a
1.5 mL microcentrifuge tube and the temperature increase
was monitored as a control.
4.6 Cell Survival Study
M059K cells (American Type Culture Collection, glioblas‐
toma) were cultured in 1:1 Modified DMEM/F-12 medium
(Hyclone, 0.1 µm sterile filtered) containing 10% foetal
bovine serum (FBS) (Seradigm, ultimate grade, triple 0.1
µm sterile filtered), 1% antibiotic/antimycotic solution
(Hyclone, 10,000 U/mL Penicillin G, 10,000 µg/mL Strepto‐
mycin, 25 µg/mL Amphotericin B, 0.2 µm filtered) in an
incubator at 37°C and 5% CO2.Cells were grown to ~80%
confluence in T75 flask (Greiner Bio-One, CELLSTAR®, red
filter cap, sterile) and passaged by washing with Dulbecco’s
phosphate buffered saline (DPBS) (Corning, cellgro,
without calcium and magnesium, sterile) and trypsinised
with 0.25% trypsin solution (Hyclone).For the RF heating
experiment, cells were harvested and counted using a
handheld automated cell counter (Millipore, Scepter™),
followed by plating 800,000 cells per flask in two T25 flasks
(Greiner Bio-One, CELLSTAR®, red filter cap, sterile) in
culture medium (5 mL). Once the cells had attached
(overnight, ~16 hours) one flask was treated with DPBS (250
µL) while the other was treated with CMPVA functional‐
ized iron oxide nanoparticles (250 µL; 2 mg/mL of Fe) and
placed back in the incubator for 24 hours. Cell medium was
removed and cells were washed with DPBS three times to
remove excess iron oxide nanoparticles. The cells were
trypsinised and counted to obtain the cell count per mL at
the start of the heating experiment. Then, aliquots of the cell
suspension (500 µL; ~100,000 cells) from the DPBS treated
group were transferred into three microcentrifuge tubes
and aliquots of the nanoparticle treated group (500 µL)
were transferred into six microcentrifuge tubes. Next, extra
nanoparticles (150 µL; 2 mg/mL of Fe) were added to three
of the six microcentrifuge tubes of the particle treated
group. One tube from each of the three groups was
subjected to either no heating, heating for 600 seconds, or
900 seconds at 200.2 A, 1284 W with a 269 kHz coil (H = 42.7
kA/m). After heating, the cells were diluted to 150 cells per
mL to plate 300 cells in medium (2 mL) per well of a six-
well plate (Greiner Bio-One, CELLSTAR®) for a colony
formation assay. These plates were incubated at 37°C for
two weeks and colonies were then counted by staining with
crystal violet.
4.7 Statistical Analysis
When applicable, values are presented as mean ± standard
error. Treatment groups in the cell survival experiment
were compared to the control using ANOVA and Dunnett
two-sided post hoc test at a 0.05 significance level. For
comparison between individual treatment groups, a Tukey
HSD post hoc test at a 0.05 significance level was utilized.
Analysis was performed using IBM SPSS Statistics 22
software.
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